Anti-infective efficacy of the lactoferrin-derived antimicrobial peptide HLR1r

Peptides

Volumn 81, Issue , 2016, Pages 21-28

  Björn, Camilla ^a,b,c   Mahlapuu, Margit ^a,c   Mattsby Baltzer, Inger ^c   Håkansson, Joakim ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SP TECHNICAL RESEARCH INSTITUTE OF SWEDEN   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

AMP; Antibiotic resistance; Candida albicans; MRSA; Staphylococcus aureus; Wound infection

Indexed keywords

ANTIFUNGAL AGENT; HLR1R PEPTIDE; INTERLEUKIN 6; LACTOFERRIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYPEPTIDE ANTIBIOTIC AGENT; PSEUDOMONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; SERPINE1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BREAST MILK; CANDIDA ALBICANS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MESOTHELIUM CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM MICROBICIDAL CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SKIN CANDIDIASIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ELECTROSPRAY MASS SPECTROMETRY; EPITHELIUM CELL; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NONPARAMETRIC TEST; PIG; WOUND INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMICROBIAL CATIONIC PEPTIDES; CANDIDA ALBICANS; CANDIDIASIS, CUTANEOUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; INTERLEUKIN-6; LACTOFERRIN; MACROPHAGES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STATISTICS, NONPARAMETRIC; SWINE; TUMOR NECROSIS FACTOR-ALPHA; WOUND INFECTION;

EID: 84966327461     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2016.04.005     Document Type: Article

References (53)

1. G.J. Moet, R.N. Jones, D.J. Biedenbach, M.G. Stilwell, and T.R. Fritsche Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004) Diagn. Microbiol. Infect. Dis. 57 2007 7 13
2. N. Kumar, M.Z. David, S. Boyle-Vavra, J. Sieth, and R.S. Daum High Staphylococcus aureus colonization prevalence among patients with skin and soft tissue infections and controls in an urban emergency department J. Clin. Microbiol. 53 2015 810 815
3. L.G. Miller, R.S. Daum, C.B. Creech, D. Young, M.D. Downing, S.J. Eells, and et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections N. Engl. J. Med. 372 2015 1093 1103
4. G.T. Ray, J.A. Suaya, and R. Baxter Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study BMC Infect. Dis. 13 2013 252
5. F. Yu, Y. Liu, J. Lv, X. Qi, C. Lu, Y. Ding, and et al. Antimicrobial susceptibility, virulence determinant carriage and molecular characteristics of Staphylococcus aureus isolates associated with skin and soft tissue infections Braz. J. Infect. Dis. 19 2015 614 622
6. S.K. Chennupati, A.G. Chiu, E. Tamashiro, C.A. Banks, M.B. Cohen, B.S. Bleier, and et al. Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis Am. J. Rhinol. Allergy 23 2009 46 51
7. C. Eckmann, and M. Dryden Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin Eur. J. Med. Res. 15 2010 554 563
8. M.S. Dryden Complicated skin and soft tissue infection J. Antimicrob. Chemother. 65 Suppl. 3 2010 iii35 44
9. L. Dijkshoorn, C.P. Brouwer, S.J. Bogaards, A. Nemec, P.J. van den Broek, and P.H. Nibbering The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii Antimicrob. Agents Chemother. 48 2004 4919 4921
10. J.L. Fox Antimicrobial peptides stage a comeback Nat. Biotechnol. 31 2013 379 382
11. N.Y. Yount, and M.R. Yeaman Emerging themes and therapeutic prospects for anti-infective peptides Annu. Rev. Pharmacol. Toxicol. 52 2012 337 360
12. R.E. Hancock, and H.G. Sahl Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies Nat. Biotechnol. 24 2006 1551 1557
13. M. Pasupuleti, A. Schmidtchen, and M. Malmsten Antimicrobial peptides: key components of the innate immune system Crit. Rev. Biotechnol. 32 2012 143 171
14. A.T. Yeung, S.L. Gellatly, and R.E. Hancock Multifunctional cationic host defence peptides and their clinical applications Cell. Mol. Life Sci. 68 2011 2161 2176
15. E. Elass-Rochard, D. Legrand, V. Salmon, A. Roseanu, M. Trif, P.S. Tobias, and et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein Infect. Immun. 66 1998 486 491
16. C.D. Fjell, J.A. Hiss, R.E. Hancock, and G. Schneider Designing antimicrobial peptides: form follows function Nat. Rev. Drug Discov. 11 2012 37 51
17. Y. Lai, and R.L. Gallo AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense Trends Immunol. 30 2009 131 141
18. A. Peschel, and H.G. Sahl The co-evolution of host cationic antimicrobial peptides and microbial resistance Nat. Rev. Microbiol. 4 2006 529 536
19. R. Eckert Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development Future Microbiol. 6 2011 635 651
20. D. Legrand, E. Elass, M. Carpentier, and J. Mazurier Lactoferrin: a modulator of immune and inflammatory responses Cell. Mol. Life Sci. 62 2005 2549 2559
21. P. Puddu, P. Valenti, and S. Gessani Immunomodulatory effects of lactoferrin on antigen presenting cells Biochimie 91 2009 11 18
22. D.S. Chapple, D.J. Mason, C.L. Joannou, E.W. Odell, V. Gant, and R.W. Evans Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111 Infect. Immun. 66 1998 2434 2440
23. D. Church, S. Elsayed, O. Reid, B. Winston, and R. Lindsay Burn wound infections Clin. Microbiol. Rev. 19 2006 403 434
24. L. Haversen, N. Kondori, L. Baltzer, L.A. Hanson, G.T. Dolphin, K. Duner, and et al. Structure-microbicidal activity relationship of synthetic fragments derived from the antibacterial α-helix of human lactoferrin Antimicrob. Agents Chemother. 54 2010 418 425
25. L. Haversen, B.G. Ohlsson, M. Hahn-Zoric, L.A. Hanson, and I. Mattsby-Baltzer Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-κβ Cell. Immunol. 220 2002 83 95
26. L.A. Haversen, L. Baltzer, G. Dolphin, L.A. Hanson, and I. Mattsby-Baltzer Anti-inflammatory activities of human lactoferrin in acute dextran sulphate-induced colitis in mice Scand. J. Immunol. 57 2003 2 10
27. L.A. Haversen, I. Engberg, L. Baltzer, G. Dolphin, L.A. Hanson, and I. Mattsby-Baltzer Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice Infect. Immun. 68 2000 5816 5823
28. N. Kondori, L. Baltzer, G.T. Dolphin, and I. Mattsby-Baltzer Fungicidal activity of human lactoferrin-derived peptides based on the antimicrobial αβ region Int. J. Antimicrob. Agents 37 2011 51 57
29. I. Mattsby-Baltzer, A. Roseanu, C. Motas, J. Elverfors, I. Engberg, and L.A. Hanson Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells Pediatr. Res. 40 1996 257 262
30. P.H. Nibbering, E. Ravensbergen, M.M. Welling, L.A. van Berkel, P.H. van Berkel, E.K. Pauwels, and et al. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria Infect. Immun. 69 2001 1469 1476
31. M. Malmsten, G. Kasetty, M. Pasupuleti, J. Alenfall, and A. Schmidtchen Highly selective end-tagged antimicrobial peptides derived from PRELP PLoS One 6 2011 e16400
32. S. Sanchez-Gomez, R. Ferrer-Espada, P.S. Stewart, B. Pitts, K. Lohner, and G. Martinez de Tejada Antimicrobial activity of synthetic cationic peptides and lipopeptides derived from human lactoferricin against Pseudomonas aeruginosa planktonic cultures and biofilms BMC Microbiol. 15 2015 137
33. A.M. van der Does, S.J. Bogaards, B. Ravensbergen, H. Beekhuizen, J.T. van Dissel, and P.H. Nibbering Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens Antimicrob. Agents Chemother. 54 2010 811 816
34. D.M. Mann, E. Romm, and M. Migliorini Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin J. Biol. Chem. 269 1994 23661 23667
35. C. Bjorn, J. Hakansson, E. Myhrman, V. Sjostrand, T. Haug, K. Lindgren, and et al. Anti-infectious and anti-inflammatory effects of peptide fragments sequentially derived from the antimicrobial peptide centrocin 1 isolated from the green sea urchin, Strongylocentrotus droebachiensis AMB Express 2 2012 67
36. E. Myhrman, J. Hakansson, K. Lindgren, C. Bjorn, V. Sjostrand, and M. Mahlapuu The novel antimicrobial peptide PXL150 in the local treatment of skin and soft tissue infections Appl. Microbiol. Biotechnol. 97 2013 3085 3096
37. P.G. Sohnle, and B.L. Hahn Epidermal proliferation and the neutrophilic infiltrates of experimental cutaneous candidiasis in mice Arch. Dermatol. Res. 281 1989 279 283
38. E. Nilsson, C. Bjorn, V. Sjostrand, K. Lindgren, M. Munnich, I. Mattsby-Baltzer, and et al. A novel polypeptide derived from human lactoferrin in sodium hyaluronate prevents postsurgical adhesion formation in the rat Ann. Surg. 250 2009 1021 1028
39. D.G. Saymen, P. Nathan, I.A. Holder, E.O. Hill, and B.G. Macmillan Infected surface wound: an experimental model and a method for the quantitation of bacteria in infected tissues Appl. Microbiol. 23 1972 509 514
40. R.E. Hancock, and G. Diamond The role of cationic antimicrobial peptides in innate host defences Trends Microbiol. 8 2000 402 410
41. M.W. Rey, S.L. Woloshuk, H.A. deBoer, and F.R. Pieper Complete nucleotide sequence of human mammary gland lactoferrin Nucleic Acids Res. 18 1990 5288
42. N. Adhirajan, N. Shanmugasundaram, S. Shanmuganathan, and M. Babu Collagen-based wound dressing for doxycycline delivery: in-vivo evaluation in an infected excisional wound model in rats J. Pharm. Pharmacol. 61 2009 1617 1623
43. C.P. Chalekson, M.W. Neumeister, and J. Jaynes Treatment of infected wounds with the antimicrobial peptide D2A21 J. Trauma 54 2003 770 774
44. Y.H. Lin, W.S. Hsu, W.Y. Chung, T.H. Ko, and J.H. Lin Evaluation of various silver-containing dressing on infected excision wound healing study J. Mater. Sci. Mater. Med. 25 2014 1375 1386
45. A. Schmidtchen, M. Pasupuleti, M. Morgelin, M. Davoudi, J. Alenfall, A. Chalupka, and et al. Boosting antimicrobial peptides by hydrophobic oligopeptide end tags J. Biol. Chem. 284 2009 17584 17594
46. A.F. Cardona, and S.E. Wilson Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment Clin. Infect. Dis. 61 Suppl. 2 2015 S69 78
47. C.D. Ciornei, T. Sigurdardottir, A. Schmidtchen, and M. Bodelsson Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37 Antimicrob. Agents Chemother. 49 2005 2845 2850
48. R.A. Dorschner, B. Lopez-Garcia, A. Peschel, D. Kraus, K. Morikawa, V. Nizet, and et al. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides FASEB J. 20 2006 35 42
49. M.J. Goldman, G.M. Anderson, E.D. Stolzenberg, U.P. Kari, M. Zasloff, and J.M. Wilson Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis Cell 88 1997 553 560
50. S. Maiti, S. Patro, S. Purohit, S. Jain, S. Senapati, and N. Dey Effective control of Salmonella infections by employing combinations of recombinant antimicrobial human β-defensins hBD-1 and hBD-2 Antimicrob. Agents Chemother. 58 2014 6896 6903
51. B. Rivas-Santiago, C.E. Rivas Santiago, J.E. Castaneda-Delgado, J.C. Leon-Contreras, R.E. Hancock, and R. Hernandez-Pando Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis Int. J. Antimicrob. Agents 41 2013 143 148
52. R.A. Dorschner, V.K. Pestonjamasp, S. Tamakuwala, T. Ohtake, J. Rudisill, V. Nizet, and et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus J. Invest. Dermatol. 117 2001 91 97
53. P.H. Mygind, R.L. Fischer, K.M. Schnorr, M.T. Hansen, C.P. Sonksen, S. Ludvigsen, and et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus Nature 437 2005 975 980